诺维本联合顺铂治疗晚期非小细胞肺癌疗效观察  

Clinical effect of navelbine and cisplatin in advanced non-small cell lung cancer.

作　　者：何仲琴 李恩孝[2] 李民[3] 锁爱莉[2] 赵晓艾[2] 李毅[2] 

机构地区：[1]陕西省宝鸡市中医医院肿瘤科,陕西宝鸡721000 [2]西安交通大学第一医院肿瘤内科,陕西西安710061 [3]西安市中心医院肿瘤科,陕西西安710003

出　　处：《现代肿瘤医学》2006年第1期50-52,共3页Journal of Modern Oncology

摘　　要：目的观察诺维本联合顺铂治疗晚期非小细胞肺癌的疗效与毒性反应。方法110例符合条件的患者接受下述联合方案化疗2~6周期,诺维本25mg/m2iv d1、8,顺铂75mg/m2iv d1或25 mg/m2iv d1~3,至少2周期进行评价。结果本组患者总有效率为48.18%;IIIA期与IV期比较疗效有显著性差异(P=0.041),而IIIB期与IV期比较、III期及IV期与复发转移者比较疗效均无显著性差别(P>0.05);鳞癌及腺癌与腺鳞癌比较疗效有显著性差异(P=0.020),而鳞癌与腺癌比较疗效无显著性差异(P>0.05);初治者疗效明显优于复治者(P=0.033)。毒性反应以骨髓抑制为主,III^IV度白细胞减少发生率61.82%,其中粒细胞减少性发热30.91%,末梢神经毒性发生率32.31%。其它不良反应耐受性良好。结论诺维本联合顺铂是治疗晚期非小细胞肺癌有效、耐受性良好和比较经济的方案,值得推广应用。Objective To study the effect and toxicity of navelbine（ NVB）and cisplatin（PDD） in advanced and relapsed non - small cell lung cancer （NSCLC）. Methods Total of 110 NSCLC patients received chemotherapy with NP as follows： navelbine 25mg/m^2 iv on day 1 and 8, cisplatin 75mg/m^2 iv on day 1 or 25 mg/m^2 on day 1 to 3, repeated every 3 weeks, at least 2 cycles for evaluating response and toxicity. Results The overall response rate was 48.18% , the response rates had significant difference between stage ⅢA and Ⅳ, P = 0. 041 ; stage ⅢB with Ⅳ, Ⅲ or Ⅳ with advanced or recurrenced NSCLC have no significant difference,P〉0.05. The response rate of squamous cell cancer and adenocarcinoma was better than that of adenosquamous carcinoma, P = 0. 020, but the response rate had no difference between squamous cell cancer and adenocarcinoma, P 〉 0.05. Initial chmotherapy was more effective than retreatment, P = 0.033. Myelosupression was the main toxicity, grade 3 and 4 neutropenia was occurred in 61.82% patients, neutraopenic fever was occurred in 30.91% patients, reversible sensory neutropathies was occurred in 32.31% patients. Other toxicities were well tolerable. Conclusion The results suggested that NP is an effective, acceptable and economic regimen in advanced and relapsed NSCLC.

关 键 词：非小细胞肺癌 诺维本 顺铂 化疗 

分 类 号：R734.2[医药卫生—肿瘤]